FWY003

DRUG2 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Geographic Atrophy Secondary to Age-related Macular DegenerationGeographic atrophy secondary to age-related macular degeneration

Phase 2

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

RecruitingNCT07441642

Novartis PharmaceuticalsGeographic Atrophy Secondary to Age-related Macular Degeneration

Start: 2026-03-09End: 2029-08-22Target: 272Updated: 2026-09-09

A randomized, double masked, placebo-controlled, multicenter, dose-range finding study to assess the efficacy and safety of FWY003 in patients with geographic atrophy secondary to age-related macular degeneration

Not yet recruitingCTIS2025-523704-77-00

Novartis Pharma AGGeographic atrophy secondary to age-related macular degeneration

Target: 44Updated: 2026-05-05